Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUDREY
2023-509509-62-00Phase 2Completed
- Sponsor
- Enterome
- Start
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 3
01
Overview
Phase 2, open-label trial of EO4010 in colorectal cancer (CRC) (3 arms), sponsored by Enterome. Primary endpoint: Safety and tolerability of EO4010 combinations. Started Jun 2024; status: completed.
02
Drugs
EO4010
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-509509-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509509-62-00.